CRVS - Corvus Pharmaceuticals GAAP EPS of -$0.21 beats by $0.02
2023-03-28 16:06:40 ET
- Corvus Pharmaceuticals press release ( NASDAQ: CRVS ): Q4 GAAP EPS of -$0.21 beats by $0.02 .
- As of December 31, 2022, Corvus had cash, cash equivalents and marketable securities totaling $42.3 million. This compared to cash, cash equivalents and marketable securities of $69.5 million as of December 31, 2021.
- Corvus expects full year 2023 net cash used in operating activities to be between approximately $19 million and $22 million, resulting in a projected cash balance of between $20 million and $23 million as of December 31, 2023. Based on its current plans, Corvus expects its cash to fund operations into 2024.
For further details see:
Corvus Pharmaceuticals GAAP EPS of -$0.21 beats by $0.02